Substance-P-mediated immunomodulation of tumor growth in a murine model

NeuroImmunoModulation

Volumn 12, Issue 4, 2005, Pages 201-210

  Manske, Jill M ^a   Hanson, Summer E ^a  

^a UNIVERSITY OF ST THOMAS   (United States)

Author keywords

Neuroimmunomodulation; Neuropeptide; Substance P; Tumor growth

Indexed keywords

SUBSTANCE P;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL FUNCTION; CELL TRANSFER; CONTROLLED STUDY; IMMUNOMODULATION; IMPLANTATION; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; SCID MOUSE; SPLEEN CELL; T LYMPHOCYTE; TUMOR GROWTH;

ADOPTIVE TRANSFER; ANIMALS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; IMMUNOLOGIC FACTORS; INFUSION PUMPS; KILLER CELLS, NATURAL; MELANOMA; MICE; MICE, INBRED C3H; MICE, NUDE; MICE, SCID; NEUROIMMUNOMODULATION; SUBSTANCE P; T-LYMPHOCYTES; TUMOR BURDEN;

EID: 21344465193     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085652     Document Type: Article

References (72)

1. Pernow B: Substance P. Pharmacol Rev 1983; 35:85-141.
2. Maggio JE: Tachykinins. Annu Rev Neurosci 1988;11:13-28.
3. Payan DG: Substance P: A modulator of neuroendocrine-immune function. Hosp Pract 1989;24:67-73.
4. Strand FL, Kenneth J, Lisa R, Lisa AZ, June K, Stephan EA, Francis JA, Lara YG: Neuropeptide hormones as neurotrophic factors. Pharmacol Rev 1991;71:1017-1046.
5. Payan DG, Goetzl EJ: Modulation of lymphocyte function by sensory neuropeptides. J Immunol 1985;135:783-786.
6. Pascual D, Xu-Amano J, Kiyono H, McGhee, JR, Bost KL: Substance P acts directly on cloned B lymphoma cells to enhance IgA and IgM production. J Immunol 1991;146:2130-2136.
7. Shanahan F, Denburg J A, Fox J, Bienenstock J, Befus D: Mast cell heterogeneity: Effects of neuroenteric peptides on histamine release. J Immunol 1985;135:1331-1337.
8. Lotz M, Carson DA, Vaughan JH: Substance P activation of rheumatoid synoviocytes: Neural pathway in pathogenesis of arthritis. Science 1987;235:893-895.
9. Hartung HP, Wolters K, Toyker KV: Substance P: Binding properties and studies on cellular responses in guinea pig macrophages. J Immunol 1986;136:3856-3863.
10. Moore TC, Lami JL, Spruck CH: Substance P increases lymphocytes traffic and lymph flow through peripheral lymph nodes of sheep. J Immunol 1989;67:109-114.
11. Calvo CF, Chavanel G, Senik A: Substance P enhances IL-2 expression in activated human T cells. J Immunol 1992;148:3498-3504.
12. Laurenzi AM, Person MAA, Dalsgaard C, Hoegerstrand A: The neuropeptide substance P stimulates production of interleukin-1 in human blood monocytes: Activated cells preferentially influenced by the neuropeptide. Scand J Immunol 1990;31:529-533.
13. Kimball ES, Persico FJ, Vaught JL: Substance P, neurokinin A, and neurokinin B induce generation of IL-1-like activity in P388D1 cells. J Immunol 1988;141:3564-3569.
14. Wagner F, Fink R, Hart R, Dancygier H: Substance P enhances interferon production by human peripheral blood mononuclear cells. Regul Pept 1987;19:355-364.
15. Rameshwar P, Ganea D, Gascon P: In vitro stimulatory effect of substance P on hematopoiesis. Blood 1993;81:391-398.
16. Rameshwar P, Gascon P: Substance P (SP) mediates production of stem cell factor and interleukin-1 in bone marrow stroma: Potential autoregulatory role for these cytokines in SP receptor expression and induction. Blood 1995;86:482-490.
17. Manske JM, Sullivan EL, Andersen SA: Substance P mediated stimulation of cytokine levels in cultured murine bone marrow stromal cells; in Atassi MZ, Bixler GS Jr (eds): The Immunobiology of Proteins and Peptides. New York, Plenum Press, 1995, vol 8, pp 53-64.
18. Regoli DG, Drapeau G, Dion S, D'Orleans-Juste P: Receptors for substance P and related neurokinins (review). Pharmacology 1989;38:1-15.
19. Levite M: Nerve-driven immunity: The direct effects of neurotransmitters on T-cell function. Ann NY Acad Sci 2000;917:307-321.
20. Lambrecht BN: Immunologists getting nervous: Neuropeptides, dendritic cells and T cell activation. Respir Res 2001;2:133-138.
21. Regoli D, Boudon A, Fauchere JL: Receptors and antagonists for substance P and related peptides. Pharmacol Rev 1994;46:551-599.
22. Marriot I, Bost KL: Expression of authentic substance P receptors in murine and human dendritic cells. J Neuroimmunol 2001;114:131-141.
23. Cheng JD, Rieger PT, von Mehren M, Adams GP, Weiner LM: Recent advances in immunotherapy and monoclonal antibody treatment of cancer. Semin Oncol Nurs 2000;16(4 suppl 1):2-12.
24. Cao L, Kulmburg P, Veelken H, Mackensen A, Mezes B, Lindemann A, Mertelsmann R, Rosenthal FM: Cytokine gene transfer in cancer therapy. Stem Cells 1998;16(suppl 1):251-260.
25. Pinilla-Ibarz J, Cathcart K, Scheinberg DA: CML vaccines as a paradigm of the specific immunotherapy of cancer. Blood Rev 2000;14:111-120.
26. Radoja S, Frey AB: Cancer-induced defective cytotoxic T lymphocyte effector function: Another mechanism how antigenic tumors escape immune-mediated killing. Mol Med 2000;6:465-479.
27. Jager D, Jager E, Knuth A: Vaccination for malignant melanoma: Recent developments. Oncology 2001;60:1-7.
28. Osterborg A, Henriksson L, Mellstedt H: Idio-type immunity (natural and vaccine-induced) in early stage multiple myeloma. Acta Oncol 2000;39:797-800.
29. Jackson PG, Evans SR: Intraperitoneal macrophages and tumor immunity: A review. J Surg Oncol 2000;75:146-154.
30. Pawelec G, Heinzel S, Kiessling R, Muller L, Ouyang Q, Zeuthen J: Escape mechanisms in tumor immunity: A year 2000 update. Crit Rev Oncog 2000;11:97-133.
31. Croitoru K, Ernst PB, Bienenstock J, Padol I, Stanisz AM: Selective modulation of the natural killer activity of murine intestinal intraepithelial leucocytes by the neuropeptide substance P. Immunology 1990;71:196-201.
32. Kimball ES, Persico FJ, Vaught JL: Substance P, neurokinin A, and neurokinin B induce generation of IL-1-like activity in P388D1 cells. Possible relevance to arthritic disease. J Immunol 1988;141:3564-3569.
33. Kimball ES: Substance P, cytokines, and arthritis. Ann NY Acad Sci 1990;594:293-308.
34. Kincy-Cain T, Bost KL: Substance P-induced IL-12 production by murine macrophages. J Immunol 1997;158:2334-2339.
35. Delgado AV, McManus AT, Chambers JP: Production of tumor necrosis factor-alpha, interleukin 1-beta, interleukin 2, and interleukin 6 by rat leukocyte subpopulations after exposure to substance P. Neuropeptides 2003;37:355-361.
36. Richard KA, Mortensen RF, Tracey DE: Cytokines involved in the augmentation of murine natural killer cell activity by pyrimidinones in vivo. J Biol Response Mod 1987;6:647-663.
37. Felten DL, Felten SY, Bellinger DL, Lorton D: Noradrenergic and peptidergic innervation of secondary lymphoid organs: Role in experimental rheumatoid arthritis. Eur J Clin Invest 1992;22(suppl 1):37-41.
38. Flageole H, Senterman M, Trudel JL: Substance P increases in vitro lymphokine-activated-killer (LAK) cell cytotoxicity against fresh colorectal cancer cells. J Surg Res 1992;53:445-449.
39. Nyeki O, Rill A, Schon I, Orosz A, Schrett J, Bartha L, Nagy J: Synthesis of peptide and pseudopeptide amides inhibiting the proliferation of small cell and epithelial types of lung carcinoma cells. J Pept Sci 1998;4:486-495.
40. Orosz A, Schrett J, Nagy J, Bartha L, Schon I, Nyeki O: New short-chain analogs of a substance-P antagonist inhibit proliferation of human small-cell lung-cancer cells in vitro and in vivo. Int J Cancer 1995;60:82-87.
41. Seckl MJ, Higgins T, Widmer F, Rozengurt E: [D-Arg1,D-Trp5,7,9,Leu11] substance P: A novel potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells. Cancer Res 1997;57:51-54.
42. MacKinnon A, Sethi T: [D-Arg6, D-Trp7,9, NmePhe8]-substance P (6-11) activates JNK and induces apoptosis in small cell lung cancer cells via an oxidant-dependent mechanism. Methods Mol Med 2003;74:299-307.
43. Harris DT, Witten M: Aerosolized substance P protects against cigarette-induced lung damage and tumor development. Cell Mol Biol 2003;49:151-157.
44. Nagakawa O, Ogasawara M, Fujii H, Murakami K, Murata J, Fuse H, Saiki I: Effect of prostatic neuropeptides on invasion and migration of PC-3 prostate cancer cells. Cancer Lett 1998;133:27-33.
45. Ogasawara M, Murata J, Ayukawa K, Saimi I: Differential effect of intestinal neuropeptides on invasion and migration of colon carcinoma cells in vitro. Cancer Lett 1997;116:111-116.
46. Palma C, Maggi CA: The role of tachykinins via NK1 receptors in progression of human gliomas. Life Sci 2000;67:985-1001.
47. Palma C, Nardelli F, Manzini S, Maggi CA: Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors. Br J Cancer 1999;79:236-243.
48. Palma C, Bigioni M, Irrissuto C, Nardelli F, Maggi CA, Manzini S: Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br J Cancer 2000;82:480-487.
49. Nowicki M, Miskowiak B: Substance P - A potent risk factor in childhood lymphoblastic leukaemia. Leukemia 2003;17:1096-1099.
50. Friess H, Zhu Z, Liard V, Shi X, Shrikhande SV, Wang L, Lieb K, Kore M, Palma C, Zimmerman A, Reubi JC, Buchler MW: Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Invest 2003;83:731-742.
51. Kripke ML: Speculations on the role of ultraviolet radiation in the development of malignant melanoma. J Natl Cancer Inst 1979;63:541-548.
52. Hostetler LW, Kripke ML: Proportion of antigenic variants induced by in vitro UV irradiation differs in clones derived from a single tumor. J Immunol 1988;140:666-670.
53. Trinchieri G: Biology of natural killer cells. Adv Immunol 1989;47:187-376.
54. Flanagan SP: 'Nude', a new hairless gene with pleiotropic effects in the mouse. Genet Res 1966;8:295-309.
55. Whiteside TL, Vujanovic NL, Herberman RB: Natural killer cells and tumor therapy. Curr Top Microbiol Immunol 1998;230:221-244.
56. Vujanovic NL, Basse P, Herberman RB, Whiteside TL: Antitumor functions of natural killer cells and control of metastases. Methods 1996;9:394-408.
57. Lang K, Drell TL, Niggemann B, Zanker KS, Entschladen F: Neurotransmitters regulate the migration and cytotoxicity in natural killer cells. Immunol Lett 2003;90:165-172.
58. Feistritzer C, Clausen J, Sturn DH, Djanani A, Gunsilius E, Wiedermann CJ, Kahler CM: Natural killer cell functions mediated by the neuropeptide substance P. Regul Pept 2003;116:119-126.
59. Pietersz GA, Apostolopoulos V, McKenzie IF: Generation of cellular immune responses to antigenic tumor peptides. Cell Mol Life Sci 2000;57:290-310.
60. Payan DG, Brewster DR, Goetzl EJ: Specific stimulation of human T lymphocytes by substance P. J Immunol 1983;131:1613-1615.
61. Payan DG, Brewster DR, Missirian-Bastian A, Goetzl EJ: Substance P recognition by a subset of human T lymphocytes. J Clin Invest 1984;74:1532-1539.
62. Elsawa SF, Taylor W, Petty CC, Marriott I, Weinstock JV, Bost KL: Reduced CTL response and increased viral burden in substance P receptor-deficient mice infected with murine gamma-herpesvirus 68. J Immunol 2003;170:2605-2612.
63. Henney CS, Kuribayashi K, Kern DE, Gillis S: Interleukin-2 augments natural killer cell activity. Nature 1981;291:335-338.
64. Konjevic G, Schlesinger B, Cheng L, Olsen KJ, Podack ER, Spuzic I: Analysis of perforin expression in human peripheral blood lymphocytes, CD56+ natural killer cell subsets and its induction by interleukin-2. Immunol Invest 1995;24:499-507.
65. Trinchieri G, Matsumoto-Kobayashi M, Clark SC, Seehra J, London L, Perussia B: Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med 1984;160:1147-1169.
66. Yu TK, Caudell EG, Smid C, Grimm EA: IL-2 activation of NK cells: Involvement of MKK1/2/ERK but not p38 kinase pathway. J Immunol 2000;164:6244-6251.
67. Rameshwar P, Gascon P, Ganea D: Immunoregulatory effects of neuropeptides. Stimulation of interleukin-2 production by substance P. J Neuroimmunol 1992;37:65-74.
68. Payan DG: Receptor-mediated mitogenic effects of substance P on cultured smooth muscle cells. Biochem Biophys Res Commun 1985;130:104-109.
69. Weidner C, Klede M, Rukwied R, Lischetzki G, Neisius U, Skov PS, Petersen LJ, Schmelz M: Acute effects of substance P and calcitonin gene-related peptide in human skin - A microdialysis study. J Invest Dermatol 2000;115:1015-1020.
70. Kito S, Shimoyama M, Arakawa R: Effects of neurotransmitters or drugs on the in vivo release of dopamine and its metabolites. Jpn J Pharmacol 1986;40:57-67.
71. Petersen LJ, Winge K, Brodin E, Skov P: No release of histamine and substance P in capsaicin-induced neurogenic inflammation in intact human skin in vivo: A microdialysis study. Clin Exp Allergy 1997;27:957-965.
72. Bowles WR, Withrow JC, Lepinski AM, Hargreaves KM: Tissue levels of immunoreactive substance P are increased in patients with irreversible pulpitis. J Endod 2003;29:265-267.